<?xml version="1.0" encoding="UTF-8"?>
<ref id="B124-vaccines-08-00468">
 <label>124.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Vassilaros</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Tsibanis</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Tsikkinis</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Pietersz</surname>
    <given-names>G.A.</given-names>
   </name>
   <name>
    <surname>McKenzie</surname>
    <given-names>I.F.</given-names>
   </name>
   <name>
    <surname>Apostolopoulos</surname>
    <given-names>V.</given-names>
   </name>
  </person-group>
  <article-title>Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1</article-title>
  <source>Immunotherapy</source>
  <year>2013</year>
  <volume>5</volume>
  <fpage>1177</fpage>
  <lpage>1182</lpage>
  <pub-id pub-id-type="doi">10.2217/imt.13.126</pub-id>
  <?supplied-pmid 24188672?>
  <pub-id pub-id-type="pmid">24188672</pub-id>
 </element-citation>
</ref>
